The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Psychedelics reopen the social reward learning critical period
Open accessAbstract
Abstract Psychedelics are a broad class of drugs defined by their ability to induce an altered state of consciousness 1,2 . These drugs have been used for millennia in both spiritual and medicinal contexts, and a number of recent clinical successes have spurred a renewed interest in developing psychedelic therapies 3–9 . Nevertheless, a unifying mechanism that can account for these shared phenomenological and therapeutic properties remains unknown. Here we demonstrate in mice that the ability to reopen the social reward learning critical period is a shared property across psychedelic drugs. Notably, the time course of critical period reopening is proportional to the duration of acute subjective effects reported in humans. Furthermore, the ability to reinstate social reward learning in adulthood is paralleled by metaplastic restoration of oxytocin-mediated long-term depression in the nucleus accumbens. Finally, identification of differentially expressed genes in the ‘open state’ versus the ‘closed state’ provides evidence that reorganization of the extracellular matrix is a common downstream mechanism underlying psychedelic drug-mediated critical period reopening. Together these results have important implications for the implementation of psychedelics in clinical practice, as well as the design of novel compounds for the treatment of neuropsychiatric disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This window represents the opening of a critical learning period, that promotes plasticity in thought, emotion, behavior, and interpersonal relationships that lasts for approximately two weeks after an MDMA session (87).”
From Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach (2025) · cites this paper as [87]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two-weeks following MDMA administration is associated with increased neuroplasticity and psychological flexibility making it an important time for integration.”
From Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach (2025) · cites this paper as [87]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This critical period is context-dependent and has been linked to the ability to induce social reward learning, psychological flexibility, cognitive reappraisal and new patterns of behavior (46, 48, 49).”
From Ayahuasca-assisted meaning reconstruction therapy for grief: a non-randomized clinical trial protocol (2025) · cites this paper as [46]
The cited source says what the claim attributes to it.
In the citing paper
“Recent studies have shown that psychedelics reopen a critical period to induce metaplasticity, which dynamically regulates the potential for synaptic plasticity (46, 47).”
From Ayahuasca-assisted meaning reconstruction therapy for grief: a non-randomized clinical trial protocol (2025) · cites this paper as [46]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
GENCODE reference annotation for the human and mouse genomes
Frankish, A., Diekhans, M., Ferreira, A.-M., Johnson, R., Jungreis, I., Loveland, J. E., Mudge, J. M., Sisu, C., Wright, J. C., Armstrong, J. C., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky955 · Cited by 3,006
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Metaplasticity: the plasticity of synaptic plasticity
Abraham, W. C., & Bear, M. F. (1996) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)80018-x · Cited by 1,833
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Trial of Psilocybin versus Escitalopram for Depression
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032994 · Cited by 1,391
Tzschentke, T. M. (2007) · Addiction Biology · doi:10.1111/j.1369-1600.2007.00070.x · Cited by 1,336
Der Kumpan in der Umwelt des Vogels
Lorenz, K. Z. (1935) · Journal für Ornithologie · doi:10.1007/bf01905355 · Cited by 1,299
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Cited by
Sorted by citations
Psilocybin desynchronizes the human brain
Siegel, J. S., Subramanian, S., Perry, D., Kay, B. P., Gordon, E. M., Laumann, T. O., Reneau, T. R., Metcalf, N. V., Chacko, R. V., Gratton, C., et al. (2024) · Nature · doi:10.1038/s41586-024-07624-5 · Cited by 308
Treatment with psychedelics is psychotherapy: beyond reductionism
Gründer, G., Brand, M., Mertens, L. J., Jungaberle, H., Kärtner, L., Scharf, D., Spangemacher, M., & Wolff, M. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00363-2 · Cited by 126
The nucleus accumbens in reward and aversion processing: insights and implications
Xu, Y., Lin, Y., Yu, M., & Zhou, K. (2024) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2024.1420028 · Cited by 86
Therapeutic mechanisms of psychedelics and entactogens
Heifets, B. D., & Olson, D. E. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01666-5 · Cited by 70
The Digital Twin Brain: A Bridge between Biological and Artificial Intelligence
Xiong, H., Chu, C., Fan, L., Song, M. X., Zhang, J., Ma, Y., Zheng, R., Zhang, J., Yang, Z., & Jiang, T. (2023) · Intelligent Computing · doi:10.34133/icomputing.0055 · Cited by 69
Weiss, F., Magnesa, A., Gambini, M., Gurrieri, R., Annuzzi, E., Elefante, C., Perugi, G., & Marazziti, D. (2025) · Brain Sciences · doi:10.3390/brainsci15020117 · Cited by 71
The polypharmacology of psychedelics reveals multiple targets for potential therapeutics
Jain, M. K., Gumpper, R. H., Slocum, S. T., Schmitz, G. P., Madsen, J. S., Tummino, T. A., Suomivuori, C., Huang, X.-P., Shub, L., DiBerto, J. F., et al. (2025) · Neuron · doi:10.1016/j.neuron.2025.06.012 · Cited by 74
MDMA and MDMA-assisted therapy
Wolfgang, A. S., Fonzo, G. A., Gray, J. C., Krystal, J. H., Grzenda, A., Widge, A. S., Kraguljac, N. V., McDonald, W. M., Rodriguez, C. I., & Nemeroff, C. B. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230681 · Cited by 62
Potential Differences in Psychedelic Actions Based on Biological Sex
Shadani, S., Conn, K., Andrews, Z. B., & Foldi, C. J. (2024) · Endocrinology · doi:10.1210/endocr/bqae083 · Cited by 62
Psychedelic-assisted psychotherapy: Where is the psychotherapy research
Aday, J. S., Horton, D., Fernandes-Osterhold, G., O’Donovan, A., Bradley, E. R., Rosen, R. C., & Woolley, J. D. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06620-x · Cited by 54
Exploring DMT: Endogenous role and therapeutic potential
Schimmelpfennig, J., & Jankowiak-Siuda, K. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110314 · Cited by 55
Targeting metaplasticity mechanisms to promote sustained antidepressant actions
Brown, K. A., & Gould, T. D. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02397-1 · Cited by 49
Agnorelli, C., Spriggs, M. J., Godfrey, K., Sawicka, G., Bohl, B., Douglass, H. M., Fagiolini, A. M., Parastoo, H., Carhart-Harris, R. L., Nutt, D. J., et al. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106132 · Cited by 65
Garel, N., Drury, J., Lévesque, J. T., Goyette, N., Lehmann, A., Looper, K. J., Erritzøe, D., Dames, S., Turecki, G., Rej, S., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1268832 · Cited by 39
A framework for assessment of adverse events occurring in psychedelic-assisted therapies
Palitsky, R., Kaplan, D. M., Perna, J., Bosshardt, Z., Maples‐Keller, J. L., Levin-Aspenson, H. F., Zarrabi, A. J., Peacock, C., Mletzko, T., Rothbaum, B. O., et al. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241265756 · Cited by 47
Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression
Ramaekers, J. G., Reckweg, J. T., & Mason, N. L. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230890 · Cited by 35
Rethinking the role of TRKB in the action of antidepressants and psychedelics
Brunello, C. A., Cannarozzo, C., & Castrén, E. (2024) · Trends in Neurosciences · doi:10.1016/j.tins.2024.08.011 · Cited by 31
Pagni, B. A., Zeifman, R. J., Mennenga, S. E., Carrithers, B. M., Goldway, N., Bhatt, S., O’Donnell, K. C., Ross, S., & Bogenschutz, M. P. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230887 · Cited by 31
Psychedelic control of neuroimmune interactions governing fear
Chung, E. N., Lee, J., Polonio, C. M., Choi, J., Akl, C. F., Kilian, M., Weiß, W. M., Gunner, G., Ye, M., Heo, T. H., et al. (2025) · Nature · doi:10.1038/s41586-025-08880-9 · Cited by 39
Comparative Pharmacological Effects of Lisuride and Lysergic Acid Diethylamide Revisited
Glatfelter, G. C., Pottie, E., Partilla, J. S., Stove, C. P., & Baumann, M. H. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00192 · Cited by 32
Human brain changes after first psilocybin use
Lyons, T., Spriggs, M., Kerkelä, L., Rosas, F. E., Roseman, L., Mediano, P. A. M., Timmermann, C., Oestreich, L., Pagni, B. A., Zeifman, R. J., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71962-3 · Cited by 30
A role for the serotonin 2A receptor in the expansion and functioning of human transmodal cortex
Luppi, A. I., Girn, M., Rosas, F. E., Timmermann, C., Roseman, L., Erritzøe, D., Nutt, D., Stamatakis, E. A., Spreng, R. N., Xing, L., et al. (2023) · Brain · doi:10.1093/brain/awad311 · Cited by 31
Efficacy and Safety of Psychedelics in Treating Anxiety Disorders
Feulner, L., Sermchaiwong, T., Rodland, N., & Galarneau, D. W. (2023) · Ochsner Journal · doi:10.31486/toj.23.0076 · Cited by 32
Floris, G., Dabrowski, K. R., Zanda, M. T., & Daws, S. E. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02788-y · Cited by 33
Epigenetic Mechanisms of Rapid-Acting Antidepressants
Inserra, A., Campanale, A., Rezai, T., Romualdi, P., & Rubino, T. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03055-y · Cited by 27
The mechanistic divide in psychedelic neuroscience: An unbridgeable gap?
Barksdale, B. R., Doss, M. K., Fonzo, G. A., & Nemeroff, C. B. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00322 · Cited by 27
A multi-institutional investigation of psilocybin’s effects on mouse behavior
Lu, O., White, K., Raymond, K. B., Liu, C. J., Klein, A. S., Green, N., Vaillancourt, S., Gallagher, A. J., Shindy, L., Li, A., et al. (2026) · Nature Neuroscience · doi:10.1101/2025.04.08.647810 · Cited by 28
Hammo, A., Wisser, S., & Cichon, J. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02068-0 · Cited by 25
Do the therapeutic effects of psilocybin involve actions in the gut?
Reed, F. M., & Foldi, C. J. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.12.007 · Cited by 26
A lexicon for psychedelic research and treatment
Nutt, D. J., Erritzøe, D., Schlag, A. K., Luke, D. P., Mash, D. C., Uchida, H., Aday, J. S., Rucker, J., Galindo, L., Sweeney, M., et al. (2025) · Drug Science Policy and Law · doi:10.1177/20503245251380511 · Cited by 24
Novel approaches to clinical trial design in cancer neuroscience
Jones, G., Anderson, J. L., Nguyen, P. T., Gleber‐Netto, F. O., Hwang, W. L., Puduvalli, V. K., Monje, M., & Amit, M. (2025) · Neuron · doi:10.1016/j.neuron.2025.08.015 · Cited by 24
Shafiee, A., Bahri, R. A., Rafiei, M. A., Abianeh, F. E., Razmara, P., Jafarabady, K., & Amini, M. J. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241234247 · Cited by 23
RetractedBedside to bench: the outlook for psychedelic research
Acero, V. P., Cribas, E. S., Browne, K. D., Rivellini, O. M., Burrell, J. C., O’Donnell, J. C., Das, S., & Cullen, D. K. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1240295 · Cited by 24
Social identity processes as a vehicle for therapeutic success in psychedelic treatment
Newson, M., Haslam, S. A., Haslam, C., Cruwys, T., & Roseman, L. (2024) · Nature Mental Health · doi:10.1038/s44220-024-00302-5 · Cited by 21
Gong, P., Wang, J., Long, H., Yang, W., Chen, X., Li, N., Chen, F., Zhang, J., & Guo, Y. (2025) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.70080 · Cited by 21
The science of psychedelic medicine
Siegel, J. S., Liston, C. M., Nicol, G. E., Carhart-Harris, R. L., & Bogenschutz, M. P. (2026) · Nature Medicine · doi:10.1038/s41591-025-04194-5 · Cited by 27
The psychedelic effects of cannabis: A review of the literature
Wolinsky, D., Barrett, F. S., & Vandrey, R. G. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231209194 · Cited by 26
Werle, I., & Bertoglio, L. J. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105899 · Cited by 24
An Update on Psychotherapy for the Treatment of PTSD
ROTHBAUM, B. O., & Watkins, L. E. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20250110 · Cited by 26
Nogueira, M., Golbert, D. C. F., de Menezes, R. S. T., de Almeida, R. N., Coelho, N. L. G., Siroky, A. N., Lima, T. Z., Maia, H., Leão, K. E., & Leão, R. N. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02655-w · Cited by 22
A sensitive period for the development of episodic-like memory in mice
Ramsaran, A. I., Ventura, S., Gallucci, J., de Snoo, M. L., Josselyn, S. A., & Frankland, P. W. (2024) · Current Biology · doi:10.1016/j.cub.2025.03.032 · Cited by 24
How Psychedelics Modulate Multiple Memory Mechanisms in Posttraumatic Stress Disorder
Doss, M. K., DeMarco, A., Dunsmoor, J. E., Cisler, J. M., Fonzo, G. A., & Nemeroff, C. B. (2024) · Drugs · doi:10.1007/s40265-024-02106-4 · Cited by 24
Psychedelics and the ‘inner healer’: Myth or mechanism?
Peill, J. M., Marguilho, M., Erritzøe, D., Barba, T., Greenway, K. T., Rosas, F. E., Timmermann, C., & Carhart-Harris, R. L. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241239206 · Cited by 24
Basedow, L. A., Majić, T., Hafiz, N. J., Algharably, E. A. E., Kreutz, R. H., & Riemer, T. (2024) · Scientific Reports · doi:10.1038/s41598-024-65391-9 · Cited by 19
Emerging mechanisms of psilocybin-induced neuroplasticity
Sonda, S., Pendin, D., Comai, S., Martin, S. D., Manfredi, P., & Mattarei, A. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.08.012 · Cited by 21
Immune-brain plasticity underpins stress and affective behaviors
Lee, J., & Wheeler, M. E. (2025) · Neuron · doi:10.1016/j.neuron.2025.11.020 · Cited by 21
Neural Geometrodynamics, Complexity, and Plasticity: A Psychedelics Perspective
Ruffini, G., Lopez-Sola, E., Vohryzek, J., & Sanchez-Todo, R. (2024) · Entropy · doi:10.3390/e26010090 · Cited by 17
Psychedelics and psychotherapy: is the whole greater than the sum of its parts
Dworkin, R. H., McDermott, M. P., Nayak, S. M., & Strain, E. C. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3050 · Cited by 17
Calder, A. E., Hase, A., & Hasler, G. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02830-z · Cited by 24
Cellular rules underlying psychedelic control of prefrontal pyramidal neuronsPreprint
Ekins, T. G., Brooks, I. A. W., Kailasa, S., Rybicki-Kler, C., Jedrasiak‐Cape, I., Donoho, E., Mashour, G. A., Rech, J. C., & Ahmed, O. J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.20.563334 · Cited by 19
Armstrong, M., Castellanos, J. P., & Christie, D. (2024) · Frontiers in Pain Research · doi:10.3389/fpain.2024.1346053 · Cited by 19
Psilocybin: From Psychiatric Pariah to Perceived Panacea
Fonzo, G. A., Wolfgang, A. S., Barksdale, B. R., Krystal, J. H., Carpenter, L. L., Kraguljac, N. V., Grzenda, A. L., McDonald, W. M., Widge, A. S., Rodríguez, C. I., et al. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230682 · Cited by 20
Utilizing Psychedelics to Enhance Well-Being: A Systematic Review
Thomson, S., & Thomacos, N. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2484380 · Cited by 16
Berkovitch, L., Fauvel, B., Preller, K. H., & Gaillard, R. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106239 · Cited by 16
Flynn, L. T., & Gao, W. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02235-4 · Cited by 16
Disrupted Human–Dog Interbrain Neural Coupling in Autism‐Associated Shank3 Mutant Dogs
Ren, W., Yu, S. P., Guo, K., Lu, C., & Zhang, Y. (2024) · Advanced Science · doi:10.1002/advs.202402493 · Cited by 22
Psychedelics and schizophrenia: a double-edged sword
Sapienza, J., Martini, F., Comai, S., Cavallaro, R., Spangaro, M., Gregorio, D. D., & Bosia, M. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02743-x · Cited by 20
Promising new pharmacological targets for depression: The search for efficacy
Tsugiyama, L. E., de Moraes, R. C. M., Moraes, Y. A. C., & de Oliveira, J. F. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103804 · Cited by 14
Psychedelic-assisted therapy among sexual and gender minority communities
Hanshaw, B. D., Fusunyan, M. A., Anderson, C. T. M., & Turban, J. L. (2024) · Nature Mental Health · doi:10.1038/s44220-024-00252-y · Cited by 15
Autism, youth suicide, and psychedelics: A review of the 21st century evidence
Chen, M., Su, T., Hsu, J.-W., & Tsai, S. (2024) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001150 · Cited by 14
Allen, S. J., & Morishita, H. (2024) · Science Advances · doi:10.1126/sciadv.adh3920 · Cited by 13
Key competencies for psychedelic treatment in real-world mental health care settings
Wolff, M., Rutrecht, H. M., Gründer, G., Jungaberle, A., & Jungaberle, H. (2025) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2025.09.003 · Cited by 15
Sakai, K., Bradley, E., Zamaria, J. A., Agin-Liebes, G., Kelley, D. P., Fish, A., Martini, V., Ferris, M. C., Morton, E. E., Michalak, E. E., et al. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06585-x · Cited by 15
Atiq, M. A., Baker, M. R., Voort, J. L. V., Vargas, M. V., & Choi, D. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06599-5 · Cited by 16
Zhang, S., Mi, P., Luan, J., Sun, M., Zhao, X. J., & Feng, X. (2024) · Environmental Research · doi:10.1016/j.envres.2024.119169 · Cited by 13
Expert recommendations for Germany’s integration of psychedelic-assisted therapy
Rosal, S. P., Torre, J. T. L., Birnkammer, S., Chernoloz, O., Williams, M. T., & Faber, S. C. (2024) · BMC Medical Education · doi:10.1186/s12909-024-06141-3 · Cited by 13
Yaden, D. B., Berghella, A. P., Hendricks, P. S., Yaden, M. E., Levine, M., Rohde, J. S., Nayak, S. M., Johnson, M. W., & Garcia‐Romeu, A. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106998 · Cited by 13
Primum non nocere: The onus to characterize the potential harms of psychedelic treatment
Ghaznavi, S., Ruskin, J. N., Haggerty, S. J., King, F., & Rosenbaum, J. F. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230914 · Cited by 12
Schmid, Y., & Bershad, A. K. (2024) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2024.02.001 · Cited by 15
Soares, C., Lima, G., Pais, M. L., Teixeira, M., Cabral, C., & Castelo-Branco, M. S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1454628 · Cited by 12
Beyond psychedelics: set and setting in general psychiatric practice
Kozak, Z., & Miller, C. W. T. (2024) · International Review of Psychiatry · doi:10.1080/09540261.2024.2419662 · Cited by 12
Borland, J. M. (2025) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2025.101175 · Cited by 13
Beretta, E., Cuboni, G., & Deidda, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125508 · Cited by 12
Psychedelic neuroplasticity of cortical neurons lacking 5-HT2A receptors
Ekins, T. G., Rybicki-Kler, C., Deng, T., Brooks, I. A. W., Jedrasiak‐Cape, I., Donoho, E., & Ahmed, O. J. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03257-w · Cited by 13
Deep CANALs: a deep learning approach to refining the canalization theory of psychopathology
Juliani, A., Safron, A., & Kanai, R. (2024) · Neuroscience of Consciousness · doi:10.1093/nc/niae005 · Cited by 12
Current perspectives on psychedelic treatments in Europe
Madero, S., Soto-Angona, Ó., Oña, G., Sánchez‐Moreno, J., & Vieta, E. (2025) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2025.101537 · Cited by 10
Antidepressants enter cells, organelles, and membranes
Blumenfeld, Z., Bera, K., Ċastrén, E., & Lester, H. A. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01725-x · Cited by 10
Structural basis of psychedelic LSD recognition at dopamine D1 receptor
Fan, L., Zhuang, Y., Wu, H., Li, H., Xu, Y., Wang, Y., He, L., Wang, S., Chen, Z., Cheng, J., et al. (2024) · Neuron · doi:10.1016/j.neuron.2024.07.003 · Cited by 12
Healing, Harms, and Humility: Expanding the Scope of Psychedelic-Assisted Psychotherapy Research
O’Donnell, K. C., Grigsby, J., & Grob, C. S. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230785 · Cited by 11
Psychoactive substances for the treatment of neuropsychiatric disorders
Zhen, Z., Sun, X., Yuan, S., & Zhang, J. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.104193 · Cited by 11
Healy, C. J., Frazier, A., Kirsch, S., Sanford, A., Garcia‐Romeu, A., Todman, M., Varon, J. P., & D'Andrea, W. M. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111361 · Cited by 9
The ABCs of psychedelics: a preclinical roadmap for drug discovery
Kwan, A. C., Mantsch, J. R., & McCorvy, J. D. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.07.017 · Cited by 10
Synaptic priming: A framework for pharmacotherapy in depression
Brown, K. A., Ajibola, M. I., Medeiros, G. C., & Gould, T. D. (2025) · Neuron · doi:10.1016/j.neuron.2025.09.010 · Cited by 11
Psychedelic medicine: mechanisms, evidence, and translation to practice
Jacobs, E., Zahid, Z., Hinkle, J. T., Nayak, S. M., & Yaden, D. B. (2026) · BMJ · doi:10.1136/bmj-2024-081723 · Cited by 9
Nair, P. C., Shajan, B., & Bastiampillai, T. J. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02466-z · Cited by 9
Neurobiology of the Antidepressant Effects of Serotonergic Psychedelics: A Narrative Review
Chisamore, N., Kaczmarek, E. S., Le, G. H., Wong, S., Orsini, D. K., Mansur, R. B., McIntyre, R. S., & Rosenblat, J. D. (2024) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-024-00319-8 · Cited by 9
Nelson, N., Miller, V. K., & Broadie, K. S. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1540052 · Cited by 11
Hilal, F. F., Jeanblanc, J., Deschamps, C., Naassïla, M., Pierrefiche, O., & Hamida, S. B. (2024) · Journal of Neural Transmission · doi:10.1007/s00702-024-02757-3 · Cited by 8
Experience-dependent serotonergic signaling in glia regulates targeted synapse elimination
Miller, V. K., & Broadie, K. S. (2024) · PLoS Biology · doi:10.1371/journal.pbio.3002822 · Cited by 8
Lin, C., Du, X., & Wang, X. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00761-5 · Cited by 8
Psilocybin as a disease-modifying drug—a salutogenic approach in psychiatry
Spangemacher, M., Mertens, L. J., Färber, L. V., Jungaberle, A., Jungaberle, H., & Gründer, G. (2024) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2024.0224 · Cited by 7
Kruger, D. J., Argyri, E. K., Mogilski, J. K., Herberholz, M., Barron, J., Aday, J. S., & Boehnke, K. F. (2025) · The Journal of Sex Research · doi:10.1080/00224499.2025.2479197 · Cited by 7
Seragnoli, F., Picard, F., Thorens, G., Buchard, A., Geyer, M., Abatista, A., Ponomarenko, P., Petignat, C., Riccardi, M., Bisson, M. D., et al. (2025) · Cognitive Therapy and Research · doi:10.1007/s10608-025-10588-z · Cited by 8
“Ontological shocks”: new transformations for sustainability through psychedelic tourism
Coghlan, A., & Prayag, G. (2025) · Journal of Sustainable Tourism · doi:10.1080/09669582.2025.2493313 · Cited by 7
Deciphering Ibogaine’s Matrix Pharmacology: Multiple Transporter Modulation at Serotonin Synapses
Hwu, C., Havel, V., Westergaard, X. O., Mendieta, A. M., Serrano, I. C., Hwu, J., Walther, D. M., Lankri, D., Selinger, T. L., He, K., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c06325 · Cited by 8
Gregory, N. S., Girard, T. E., Ram, A., Casey, A. B., Malenka, R. C., Tawfik, V. L., & Heifets, B. D. (2026) · Nature Communications · doi:10.1038/s41467-026-68763-z · Cited by 7
Tyagi, R., Saraf, T. S., & Canal, C. E. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00137 · Cited by 7
Zhai, H., Wang, Y., & Wang, X. (2024) · Neuroscience Bulletin · doi:10.1007/s12264-024-01341-9 · Cited by 7
Harnessing psychedelics for stroke recovery: therapeutic potential and mechanisms
Yang, Y., Wang, Y., & Wang, X. (2025) · Brain · doi:10.1093/brain/awaf093 · Cited by 7
Psychedelic treatments are speeding towards approval — but no one knows how they work
Reardon, S. (2023) · Nature · doi:10.1038/d41586-023-03334-6 · Cited by 7
Metadata
- Authors
- Nardou, R., Sawyer, E., Song, Y. J., Wilkinson, M., Padovan-Hernandez, Y., de Deus, J. L., Wright, N., Lama, C., Faltin, S., Goff, L. A., Stein-O’Brien, G. L., & Dölen, G.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Dölen, Gül
- ORCID
- Venue
- Nature
- Published
- 2023-06-14
- Volume
- 618
- Issue
- 7966
- Pages
- 790-798
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC10284704
- OpenAlex
- W4380684709
- Cited by
- 358
- References
- 72
- Citations by year
- 2026: 100 · 2025: 147 · 2024: 80 · 2023: 30
- FWCI
- 104.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Nature (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Johns Hopkins University
- National Institutes of Health
- National Institute on Aging (R01AG066768, R01AG072305)
- National Institute of Mental Health (R01MH117127)
- National Institute on Drug Abuse
- National Institute of General Medical Sciences (R25GM109441)
- National Institute of Neurological Disorders and Stroke (K99NS122085, R00NS122085)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD098184)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- psychedelics, metaplasticity, oxytocin, long-term depression, nucleus accumbens, extracellular matrix remodeling, subjective effects, altered states of consciousness
- MeSH terms
- Animals, Consciousness, Critical Period, Psychological, Extracellular Matrix, Hallucinogens, Humans, Learning, Nucleus Accumbens, Oxytocin, Reward, Time Factors, Long-Term Synaptic Depression, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review